Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD, 4102, Australia.
School of Medicine, University of Queensland, Brisbane, QLD, Australia.
Surg Endosc. 2021 Feb;35(2):684-692. doi: 10.1007/s00464-020-07433-7. Epub 2020 Mar 25.
Lesions involving the ampulla of Vater have traditionally been managed by surgical resection, albeit with high rates of morbidity and mortality. Endoscopic ampullectomy is increasingly recognized as an efficacious and safer treatment option. This study aims to evaluate the safety and efficacy of endoscopic ampullectomy for non-invasive ampullary lesions in a single tertiary referral center.
Patients with non-invasive ampullary lesions, with or without familial adenomatous polyposis (FAP), were identified using pathology and endoscopy databases. The study included all patients who underwent the index ampullectomy between January 2007 and January 2017. Outcome parameters included accuracy of forceps biopsies, adverse events, success of endoscopic resection, and rate of recurrence.
A total of 53 patients underwent endoscopic ampullectomy over the 10-year period. Histological upstaging was seen in 37.8% of cases at ampullectomy compared to biopsy, including 5 cases (9.4%) of invasive adenocarcinoma. Adverse events occurred in 10 patients (18.9%) consisting of bleeding (11.3%), benign papillary stenosis (3.8%), acute pancreatitis (1.9%), and duodenal perforation (1.9%). Recurrence occurred in 32.7% over a median follow-up of 30 months (range 6-104 months), with the majority (18.4%) occurring at the first surveillance endoscopy. Nonetheless, 75% of recurrences were able to be cleared endoscopically. Endoscopic resection was successful in 91.1% of patients.
Endoscopic ampullectomy is an effective and safer therapeutic modality for non-invasive ampullary lesions, in addition to being a valuable diagnostic and staging tool. Nevertheless, careful patient selection and a commitment to endoscopic follow-up are of primary importance to achieve an optimal therapeutic outcome.
传统上,壶腹区域的病变一直采用手术切除的方式进行治疗,尽管手术的发病率和死亡率较高。内镜壶腹切除术已被越来越多地认为是一种有效且更安全的治疗选择。本研究旨在评估在一家三级转诊中心,内镜壶腹切除术治疗非侵袭性壶腹病变的安全性和疗效。
使用病理学和内镜数据库,确定存在或不存在家族性腺瘤性息肉病(FAP)的非侵袭性壶腹病变患者。本研究包括 2007 年 1 月至 2017 年 1 月期间进行索引性壶腹切除术的所有患者。研究结果参数包括活检钳活检的准确性、不良事件、内镜切除的成功率以及复发率。
在 10 年期间,共有 53 例患者接受了内镜壶腹切除术。与活检相比,壶腹切除术时发现组织学升级的比例为 37.8%,包括 5 例(9.4%)侵袭性腺癌。10 例(18.9%)患者发生了不良事件,包括出血(11.3%)、良性乳头狭窄(3.8%)、急性胰腺炎(1.9%)和十二指肠穿孔(1.9%)。中位随访 30 个月(6-104 个月)后,有 32.7%的患者复发,其中大多数(18.4%)在首次监测内镜检查时复发。尽管如此,75%的复发能够通过内镜清除。91.1%的患者内镜切除成功。
内镜壶腹切除术是一种有效且更安全的治疗非侵袭性壶腹病变的方法,同时也是一种有价值的诊断和分期工具。然而,仔细选择患者并承诺进行内镜随访对于获得最佳治疗效果至关重要。